HRP20192270T4 - Konjugirane čestice peptida - Google Patents
Konjugirane čestice peptida Download PDFInfo
- Publication number
- HRP20192270T4 HRP20192270T4 HRP20192270TT HRP20192270T HRP20192270T4 HR P20192270 T4 HRP20192270 T4 HR P20192270T4 HR P20192270T T HRP20192270T T HR P20192270TT HR P20192270 T HRP20192270 T HR P20192270T HR P20192270 T4 HRP20192270 T4 HR P20192270T4
- Authority
- HR
- Croatia
- Prior art keywords
- gluten
- preparation according
- carboxylation
- particle
- peptide conjugated
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 108010068370 Glutens Proteins 0.000 claims 4
- 235000021312 gluten Nutrition 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 2
- 230000021523 carboxylation Effects 0.000 claims 2
- 238000006473 carboxylation reaction Methods 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000006557 surface reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (4)
1. Pripravak koji sadrži površinski funkcionalizirane biorazgradive čestice koje sadrže inkapsulirani glutenski epitop ili jedan ili više antigenih glutenskih epitopa, naznačen time što čestica ima negativan zeta potencijal i naznačen time što je navedena čestica promjera između 0.1 μm i 10 μm, i naznačen time što glutenski epitop ili jedan ili više antigenih glutenskih epitopa sadrži jedan ili više sekvenci navedenih u SEQ ID NOS: 1295-1724, 1726-1766, 4983-4985 i 4986-5140.
2. Pripravak prema zahtjevu 1, naznačen time što čestice sadrže poli (laktid-ko-glikolid) (PLG).
3. Pripravak prema zahtjevu 1, naznačen time što površinska funkcionalizacija je karboksilacija, izborno naznačen time što se karboksilacija postiže se uporabom poli (etilen-maleinskog anhidrida) (PEMA).
4. Pripravak prema zahtjevu 1, nadalje sadrži farmaceutski prihvatljive ekscipijente.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865389P | 2013-08-13 | 2013-08-13 | |
US201361869279P | 2013-08-23 | 2013-08-23 | |
US201361887112P | 2013-10-04 | 2013-10-04 | |
EP14836306.2A EP3033102B2 (en) | 2013-08-13 | 2014-08-13 | Peptide conjugated particles |
PCT/US2014/050962 WO2015023796A2 (en) | 2013-08-13 | 2014-08-13 | Peptide conjugated particles |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20192270T1 HRP20192270T1 (hr) | 2020-06-12 |
HRP20192270T4 true HRP20192270T4 (hr) | 2024-03-01 |
Family
ID=52468804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192270TT HRP20192270T4 (hr) | 2013-08-13 | 2014-08-13 | Konjugirane čestice peptida |
Country Status (24)
Country | Link |
---|---|
US (9) | US9616113B2 (hr) |
EP (2) | EP3033102B2 (hr) |
JP (4) | JP6553033B2 (hr) |
KR (5) | KR20160042079A (hr) |
CN (2) | CN105555301B (hr) |
AU (4) | AU2014306603B2 (hr) |
BR (1) | BR112016003084A2 (hr) |
CA (1) | CA2918823A1 (hr) |
CY (1) | CY1122558T1 (hr) |
DK (1) | DK3033102T4 (hr) |
ES (1) | ES2762187T5 (hr) |
FI (1) | FI3033102T4 (hr) |
HR (1) | HRP20192270T4 (hr) |
HU (1) | HUE047329T2 (hr) |
IL (3) | IL292567A (hr) |
LT (1) | LT3033102T (hr) |
ME (1) | ME03590B (hr) |
MX (5) | MX2016001931A (hr) |
PL (1) | PL3033102T5 (hr) |
PT (1) | PT3033102T (hr) |
RS (1) | RS59801B2 (hr) |
RU (1) | RU2685186C2 (hr) |
SI (1) | SI3033102T2 (hr) |
WO (1) | WO2015023796A2 (hr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5909745B2 (ja) | 2010-11-12 | 2016-04-27 | クール ファーマシューティカルズ ディベロップメント カンパニー | 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬 |
WO2013163176A1 (en) | 2012-04-23 | 2013-10-31 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
RU2669346C2 (ru) | 2012-06-21 | 2018-10-10 | Норсвестерн Юниверсити | Частицы, конъюгированные с пептидами |
KR20230025948A (ko) | 2013-03-13 | 2023-02-23 | 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. | 염증 치료용 면역-변형된 입자 |
CA2907915C (en) | 2013-04-03 | 2023-03-07 | Allertein Therapeutics, Llc | Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components |
LT3033102T (lt) | 2013-08-13 | 2020-03-10 | Northwestern University | Dalelės, konjuguotos su peptidu |
EP4299058A3 (en) | 2014-06-24 | 2024-03-27 | The Trustees of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
EP3095440B1 (en) * | 2015-05-19 | 2020-01-15 | PLS-Design GmbH | Antigen-specific immunotherapy using tolerizing liposomes |
US20180282383A1 (en) | 2015-10-02 | 2018-10-04 | University Of Copenhagen | Small molecules blocking histone reader domains |
AU2016378743A1 (en) | 2015-12-22 | 2018-08-02 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
EP3393514A4 (en) | 2015-12-23 | 2019-08-14 | Cour Pharmaceuticals Development Company Inc. | PARTICLES CONJUGATED BY COVALENCE OF THE POLYMER-ANTIGEN TYPE |
IL260296B2 (en) * | 2016-01-04 | 2024-01-01 | Cour Pharmaceuticals Dev Company Inc | Particles thermalize fusion proteins containing associated epitopes |
JP2019504895A (ja) * | 2016-02-09 | 2019-02-21 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | スギ花粉エピトープを封入するtimp(組織性メタロプロテアーゼ阻害因子) |
EP3416624B8 (en) * | 2016-02-18 | 2023-08-23 | Cour Pharmaceuticals Development Company Inc. | Process for the preparation of tolerizing immune-modulating particles |
WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
US20210030892A1 (en) | 2018-02-08 | 2021-02-04 | Cour Pharmaceuticals Development Company Inc. | Treatment of celiac disease with tolerizing particles |
US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
US20210382050A1 (en) | 2018-10-19 | 2021-12-09 | The Regents Of The University Of Michigan | Method for monitoring autoimmune disease |
AU2020253637A1 (en) * | 2019-04-05 | 2021-12-02 | Asp Health Inc. | Consumable components in fluidic sample dispensing systems and methods |
CN110317255B (zh) * | 2019-07-19 | 2020-07-31 | 北京工商大学 | αs1-酪蛋白的抗原表位制备得到的单抗及牛乳过敏原检测方法 |
EP4021490A4 (en) * | 2019-08-30 | 2023-10-25 | Universidad De Chile | AUTOANTIGEN PEPTIDES (CALVICIFIV), PRESENTED BY TOLEROGENED DENTRIC CELLS, FOR THE PERSONALIZED TREATMENT OF RHEUMATOID ARTHRITIS |
GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
JP7471688B2 (ja) * | 2019-12-03 | 2024-04-22 | 中國醫藥大學 | オリゴペプチド、検出キット及び医薬組成物 |
WO2021155281A1 (en) * | 2020-01-31 | 2021-08-05 | Applied Molecular Transport Inc. | Compositions and methods for treatment of celiac disease |
CA3174689A1 (en) * | 2020-03-20 | 2021-09-23 | Monash University | Compositions and methods for treating lupus |
ES2963150T3 (es) * | 2020-10-27 | 2024-03-25 | Elucida Oncology Inc | Procedimientos para funcionalizar nanopartículas |
CN117396757A (zh) | 2021-04-16 | 2024-01-12 | 库尔制药开发公司 | 追踪免疫耐受的维持的方法 |
WO2022221619A1 (en) * | 2021-04-16 | 2022-10-20 | Cour Pharmaceuticals Development Company Inc. | Treatment of peanut allergy with tolerizing nanoparticles |
IL312097A (en) | 2021-10-21 | 2024-06-01 | Cour Pharmaceuticals Dev Company Inc | Treatment of primary biliary cirrhosis (PBC) with tolerable nanoparticles |
CN113908256B (zh) * | 2021-11-26 | 2023-05-26 | 中国农业科学院兰州兽医研究所 | Lancl1蛋白在制备抗病毒药物中的应用 |
CN114773434B (zh) * | 2022-03-17 | 2024-04-05 | 南京市妇幼保健院 | 一种用于激活原始卵泡从而治疗或辅助治疗卵巢早衰的多肽pfap1及其应用 |
TW202400801A (zh) | 2022-04-29 | 2024-01-01 | 美商庫爾製藥發展公司股份有限公司 | 用於克服治療性載體及蛋白質之免疫原性之耐受性免疫修飾奈米粒子 |
GB202211696D0 (en) * | 2022-08-10 | 2022-09-21 | Univ London Queen Mary | Peptides and method |
WO2024072751A1 (en) * | 2022-09-26 | 2024-04-04 | The Methodist Hospital | Microparticle formulations for intravenous therapy and methods for their manufacture and use |
WO2024086706A1 (en) | 2022-10-19 | 2024-04-25 | Cour Pharmaceuticals Development Company Inc. | Treatment of peanut allergy with tolerizing nanoparticles |
WO2024094562A1 (en) * | 2022-11-01 | 2024-05-10 | Universität Zürich | Novel mbp peptides and their use in the treatment of multiple sclerosis |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3512940A (en) | 1968-12-30 | 1970-05-19 | Justin J Shapiro | Test tube filter device |
GB8311730D0 (en) | 1983-04-29 | 1983-06-02 | Bagshawe K D | Handling of reaction mixtures |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4990253A (en) | 1988-01-25 | 1991-02-05 | Abbott Laboratories | Fluid sample filtration device |
US5358690A (en) | 1989-01-10 | 1994-10-25 | Lamina, Ltd. | Environmental sample collection and membrane testing device |
DE9013914U1 (de) | 1990-10-05 | 1991-02-14 | Walter Sarstedt Geräte und Verbrauchsmaterial für Medizin und Wissenschaft, 5223 Nümbrecht | Trennvorrichtung für Flüssigkeits-, insbesondere Blutfraktionen |
EP0627933B1 (en) | 1992-02-28 | 2002-11-27 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
JPH06157592A (ja) | 1992-11-24 | 1994-06-03 | Hitachi Chem Co Ltd | ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−1抗体の製造方法 |
NZ266739A (en) | 1993-06-02 | 1997-07-27 | Tvw Telethon Inst Child Health | Inducing immunologic tolerance by administering a cryptic peptide derived from the antigen der pi |
US5833860A (en) | 1995-08-28 | 1998-11-10 | Millipore Investment Holdings Limited | Centrifugal adsorptive sample preparation device and method |
US5804201A (en) | 1996-03-11 | 1998-09-08 | The Rockefeller University | Immunomodulatory peptides of vespid antigen 5 |
AU736102B2 (en) | 1997-03-31 | 2001-07-26 | Regents Of The University Of Michigan, The | Open pore biodegradable matrices |
US7427602B1 (en) | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
DE69937580D1 (de) | 1999-08-18 | 2007-12-27 | Ind Academic Coop | Agent zur induktion einer immunologischen toleranz |
WO2001039800A2 (en) * | 1999-12-06 | 2001-06-07 | The Board Of Trustees Of The University Of Arkansas | Controlled delivery of antigens |
CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
US7332168B2 (en) | 2000-08-22 | 2008-02-19 | Micromet Ag | Composition for the elimination of autoreactive B-cells |
US7029697B2 (en) | 2001-02-14 | 2006-04-18 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
US6890556B1 (en) | 2001-02-14 | 2005-05-10 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
US20020187147A1 (en) * | 2001-02-15 | 2002-12-12 | City Of Hope | Antigen specific recombinant MHC class II molecules and methods of use |
CA2465779A1 (en) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
ATE491471T1 (de) | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
WO2003092654A1 (en) | 2002-05-02 | 2003-11-13 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
EP1551449B1 (en) | 2002-07-12 | 2010-10-06 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
US7465463B2 (en) | 2002-09-04 | 2008-12-16 | Polyheal, Ltd. | Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
AU2003302226A1 (en) * | 2002-09-24 | 2004-06-30 | University Of Kentucky Research Foundation | Nanoparticle-based vaccine delivery system containing adjuvant |
US20050002999A1 (en) * | 2003-06-04 | 2005-01-06 | Rahul Mehta | Long-circulating liposomal compositions |
US20060051407A1 (en) | 2003-06-27 | 2006-03-09 | Yoram Richter | Method of treating ischemia-reperfusion injury |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
WO2005015160A2 (en) | 2003-08-07 | 2005-02-17 | The Children's Hospital Of Philadelphia | Functionalized polymeric colloids |
WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
WO2005020933A2 (en) | 2003-09-02 | 2005-03-10 | University Of South Florida | Nanoparticles for drug-delivery |
EP1687024B1 (en) | 2003-11-05 | 2011-10-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
US7885411B2 (en) | 2004-04-02 | 2011-02-08 | Research In Motion Limited | Key agreement and re-keying over a bidirectional communication path |
US7846466B2 (en) | 2004-06-10 | 2010-12-07 | Northwestern University | Biodegradable scaffolds and uses thereof |
CA2571899A1 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
JP4933455B2 (ja) | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー/エス | 新規のインスリン誘導体 |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
EP1904932A4 (en) | 2005-06-17 | 2013-02-27 | Univ North Carolina | METHODS, SYSTEMS AND MATERIALS FOR MANUFACTURING NANOPARTICLES |
CA2610973A1 (en) * | 2005-07-01 | 2007-01-11 | F. Hoffmann-La Roche Ag | Carboxylated latex particles |
WO2007008755A2 (en) | 2005-07-08 | 2007-01-18 | The Board Of Regents, The University Of Texas System | Surface functionalization of polymeric materials |
GB0514262D0 (en) * | 2005-07-12 | 2005-08-17 | Renovo Ltd | Promotion of epithelial regeneration |
US20070041934A1 (en) | 2005-08-12 | 2007-02-22 | Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
JP2009519975A (ja) * | 2005-12-16 | 2009-05-21 | ユニバーシティ・オブ・カンザス | 治療薬を送達するナノクラスター |
WO2007087341A2 (en) | 2006-01-25 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Tolerogenic biodegradable artificial antigen presenting system |
WO2007094003A2 (en) * | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
KR20090003310A (ko) | 2006-03-02 | 2009-01-09 | 씨바이오 리미티드 | 항원 제시 세포의 기능 조절에 의한 면역 반응의 조절 |
JP2009533453A (ja) * | 2006-04-11 | 2009-09-17 | オードウェイ リサーチ インスティテュート | 甲状腺ホルモン類似体、アンタゴニストおよびそれらの製剤のためのナノ粒子およびポリマー製剤 |
EP2061446A2 (en) * | 2006-07-28 | 2009-05-27 | University Court of the University of Edinburgh | Use of cdk inhibitors for the treatment of granulocyte mediated disorders |
CA2702340C (en) * | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
US20090214474A1 (en) | 2006-11-01 | 2009-08-27 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
RU2481125C2 (ru) | 2006-12-18 | 2013-05-10 | Колороббия Италия С.П.А. | Магнитные наночастицы для применения при гипертермии, их приготовление и применение в магнитных системах для фармакологического использования |
EP2842570B1 (en) | 2007-03-07 | 2020-05-06 | UTI Limited Partnership | Compositions and methods for the prevention and treatment of autoimmune conditions |
US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
EP2211841A4 (en) | 2007-10-15 | 2013-03-13 | Cooperative Res Ct For Asthma | PROPHYLAXIS METHOD AND AGENTS FOR USE IN THIS METHOD |
WO2009052561A1 (en) | 2007-10-22 | 2009-04-30 | The Walter And Eliza Hall Institute Of Medical Research | Compositions and methods for manipulating an immune response |
EP2057998A1 (en) | 2007-10-31 | 2009-05-13 | Universitätsklinikum Hamburg-Eppendorf | Use of modified cells for the treatment of multiple sclerosis |
US20090123509A1 (en) * | 2007-11-08 | 2009-05-14 | Cory Berkland | Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds |
US20090238879A1 (en) | 2008-01-24 | 2009-09-24 | Northwestern University | Delivery scaffolds and related methods of use |
JP2009203174A (ja) | 2008-02-26 | 2009-09-10 | Hokkaido Univ | タンパク質−リポソーム複合体を含有するイオントフォレーシス用組成物 |
CA2722184A1 (en) | 2008-04-25 | 2009-10-29 | Duke University | Regulatory b cells and their uses |
EP2123261A1 (en) | 2008-05-20 | 2009-11-25 | Stallergenes S.A. | Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance |
US20110206773A1 (en) | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
WO2010037142A1 (en) * | 2008-09-29 | 2010-04-01 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
MX2011003569A (es) | 2008-10-02 | 2011-06-09 | Univ Pittsburgh | Administracion de un polimero adsorbente para el tratamiento de inflamacion sistemica. |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
JP5851243B2 (ja) * | 2008-11-30 | 2016-02-03 | イミューサンティー インコーポレーテッドImmusanT,Inc. | セリアック病の処置のための組成物および方法 |
EP2376115A4 (en) | 2008-12-11 | 2013-07-03 | Univ Alberta | METHODS AND SYSTEMS FOR INDUCING IMMUNOLOGICAL TOLERANCE TO NON-NONE ANTIGENS |
US20120076831A1 (en) | 2009-01-20 | 2012-03-29 | Stephen Miller | Compositions and methods for induction of antigen-specific tolerance |
EP2255831A1 (en) * | 2009-05-25 | 2010-12-01 | Institut Pasteur | Liposome based diepitope constructs |
EA028288B1 (ru) | 2009-05-27 | 2017-10-31 | Селекта Байосайенсиз, Инк. | Наноносители, имеющие компоненты с различными скоростями высвобождения |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
JP5486750B2 (ja) | 2009-09-18 | 2014-05-07 | 国立大学法人九州大学 | 金微粒子被覆体とその製造方法、およびその用途 |
RU2448685C2 (ru) * | 2009-11-30 | 2012-04-27 | Российская Федерация в лице Министерства промышленности и торговли Российской Федерации | Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза |
US20110135744A1 (en) | 2009-12-03 | 2011-06-09 | The Regents Of The University Of California | Nanoparticle Based Therapy for Dispersing Mucin |
EP2538969A4 (en) * | 2010-02-22 | 2013-11-27 | Liquidia Technologies Inc | VACCINES FROM POLYSACCHARIDE PARTICLES |
WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US9168225B2 (en) * | 2010-04-23 | 2015-10-27 | The Board Of Trustees Of The University Of Illinois | Nano-hybrid delivery system for sequential utilization of passive and active targeting |
WO2011153532A1 (en) | 2010-06-04 | 2011-12-08 | Flow Pharma Inc. | Peptide particle formulation |
US8907015B2 (en) | 2010-06-04 | 2014-12-09 | Tongji University | Copolymer of pyrene and pyrrole and method of producing the copolymer |
AU2011272941B2 (en) | 2010-06-30 | 2014-05-29 | Compugen Ltd. | C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
CN103037898B (zh) * | 2010-07-07 | 2016-06-29 | 人工细胞科技公司 | 呼吸道合胞病毒抗原组合物和方法 |
EP2598120B1 (en) | 2010-07-31 | 2018-09-05 | The Scripps Research Institute | Compositions and methods for inducing immune tolerance |
WO2012019041A2 (en) | 2010-08-04 | 2012-02-09 | Duke University | Regulatory b cells and their uses |
JP5909745B2 (ja) | 2010-11-12 | 2016-04-27 | クール ファーマシューティカルズ ディベロップメント カンパニー | 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬 |
US20130295186A1 (en) | 2010-11-24 | 2013-11-07 | Say Chye Joachim Loo | Method for coating particles with calcium phosphate and particles, microparticles and nanoparticles formed thereof |
US10064406B2 (en) | 2011-01-06 | 2018-09-04 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
EP2667844B1 (en) * | 2011-01-24 | 2018-11-21 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Nanoparticles for dermal and systemic delivery of drugs |
CA2828255A1 (en) * | 2011-02-25 | 2012-08-30 | South Dakota State University | Protein nanocarriers for topical delivery |
WO2012149405A2 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for regulating innate immune responses |
EP2736537A4 (en) | 2011-07-29 | 2015-04-15 | Selecta Biosciences Inc | SYNTHETIC NANOTRANSPORTERS FOR THE PRODUCTION OF HUMOROUS AND CYTOTOXIC T-LYMPHOCY (CTL) IMMUNE REACTIONS |
WO2013036297A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Therapeutic protein-specific induced tolerogenic dendritic cells and methods of use |
WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013115965A1 (en) * | 2012-01-31 | 2013-08-08 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
RU2669346C2 (ru) † | 2012-06-21 | 2018-10-10 | Норсвестерн Юниверсити | Частицы, конъюгированные с пептидами |
KR20230025948A (ko) | 2013-03-13 | 2023-02-23 | 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. | 염증 치료용 면역-변형된 입자 |
LT3033102T (lt) * | 2013-08-13 | 2020-03-10 | Northwestern University | Dalelės, konjuguotos su peptidu |
CA2927393A1 (en) * | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
-
2014
- 2014-08-13 LT LTEP14836306.2T patent/LT3033102T/lt unknown
- 2014-08-13 KR KR1020167006265A patent/KR20160042079A/ko not_active Application Discontinuation
- 2014-08-13 CN CN201480046047.XA patent/CN105555301B/zh active Active
- 2014-08-13 WO PCT/US2014/050962 patent/WO2015023796A2/en active Application Filing
- 2014-08-13 CN CN202110339093.0A patent/CN113332422A/zh active Pending
- 2014-08-13 SI SI201431436T patent/SI3033102T2/sl unknown
- 2014-08-13 HR HRP20192270TT patent/HRP20192270T4/hr unknown
- 2014-08-13 IL IL292567A patent/IL292567A/en unknown
- 2014-08-13 JP JP2016534825A patent/JP6553033B2/ja active Active
- 2014-08-13 RU RU2016107998A patent/RU2685186C2/ru active
- 2014-08-13 HU HUE14836306A patent/HUE047329T2/hu unknown
- 2014-08-13 PL PL14836306.2T patent/PL3033102T5/pl unknown
- 2014-08-13 FI FIEP14836306.2T patent/FI3033102T4/fi active
- 2014-08-13 KR KR1020217024418A patent/KR102485789B1/ko active IP Right Grant
- 2014-08-13 MX MX2016001931A patent/MX2016001931A/es active IP Right Grant
- 2014-08-13 ES ES14836306T patent/ES2762187T5/es active Active
- 2014-08-13 AU AU2014306603A patent/AU2014306603B2/en active Active
- 2014-08-13 PT PT148363062T patent/PT3033102T/pt unknown
- 2014-08-13 KR KR1020247002210A patent/KR20240015725A/ko active Application Filing
- 2014-08-13 KR KR1020227019686A patent/KR20220084202A/ko not_active Application Discontinuation
- 2014-08-13 RS RS20191620A patent/RS59801B2/sr unknown
- 2014-08-13 EP EP14836306.2A patent/EP3033102B2/en active Active
- 2014-08-13 KR KR1020237000033A patent/KR20230008909A/ko not_active Application Discontinuation
- 2014-08-13 DK DK14836306.2T patent/DK3033102T4/da active
- 2014-08-13 EP EP19204340.4A patent/EP3650047A1/en active Pending
- 2014-08-13 CA CA2918823A patent/CA2918823A1/en active Pending
- 2014-08-13 BR BR112016003084A patent/BR112016003084A2/pt not_active Application Discontinuation
- 2014-08-13 ME MEP-2019-345A patent/ME03590B/me unknown
-
2015
- 2015-02-17 US US14/624,463 patent/US9616113B2/en active Active
- 2015-04-03 US US14/678,863 patent/US9522180B2/en active Active
-
2016
- 2016-01-17 IL IL243632A patent/IL243632B/en active IP Right Grant
- 2016-02-12 MX MX2023000194A patent/MX2023000194A/es unknown
- 2016-02-12 MX MX2020007079A patent/MX2020007079A/es unknown
- 2016-02-12 MX MX2023000192A patent/MX2023000192A/es unknown
- 2016-02-12 MX MX2020004799A patent/MX2020004799A/es unknown
- 2016-11-02 US US15/341,935 patent/US10188711B2/en active Active
-
2017
- 2017-03-08 US US15/453,807 patent/US11160851B2/en active Active
-
2018
- 2018-03-15 US US15/922,241 patent/US10617747B2/en active Active
-
2019
- 2019-07-03 JP JP2019124323A patent/JP7007335B2/ja active Active
- 2019-12-10 CY CY20191101296T patent/CY1122558T1/el unknown
-
2020
- 2020-03-25 IL IL273615A patent/IL273615B/en unknown
- 2020-04-13 US US16/847,450 patent/US11129881B2/en active Active
- 2020-04-17 US US16/852,205 patent/US20210000932A1/en not_active Abandoned
- 2020-06-10 AU AU2020203822A patent/AU2020203822B2/en active Active
- 2020-06-10 AU AU2020203824A patent/AU2020203824B2/en active Active
-
2021
- 2021-06-30 US US17/364,351 patent/US11389517B2/en active Active
- 2021-08-16 JP JP2021132266A patent/JP7408604B2/ja active Active
- 2021-09-22 US US17/482,043 patent/US20220008523A1/en active Pending
-
2023
- 2023-08-21 AU AU2023219813A patent/AU2023219813A1/en active Pending
- 2023-12-20 JP JP2023214611A patent/JP2024037982A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192270T4 (hr) | Konjugirane čestice peptida | |
JP2016529698A5 (hr) | ||
TWD172449S (zh) | 自走式電動吸塵器 | |
JP2016510668A5 (hr) | ||
CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
JP2016124096A5 (hr) | ||
EP4275665A3 (en) | Three dimensional devices for prolapse alleviation | |
JP2015514231A5 (hr) | ||
BR112015029438A2 (pt) | corpo de sucção com coxim separável | |
TWD178669S (zh) | 發光裝置之部分 | |
EA201592292A1 (ru) | Инъекционное устройство | |
JP2015222930A5 (hr) | ||
EA201991117A1 (ru) | Системы и способы улучшенного поддержания высокоэффективной конфигурации с обращенным полем с вакуумированием с захватом многомасштабного типа | |
JP2016525403A5 (hr) | ||
WO2015120378A8 (en) | Porcine epidemic diarrhea virus (pedv) proteins and antigens | |
JP2016535411A5 (hr) | ||
FR3051637A1 (fr) | Parapluie gonflable | |
Kang et al. | Three-Dimensional Self-Assembly of Gold Nanoparticles Using a Virus Scaffold | |
CN105559142A (zh) | 烟灰缸 | |
USD829916S1 (en) | Bite block device | |
JP2012142115A5 (hr) | ||
Hwang et al. | Development of the Quantum Dot/ZnO Nanowire Heterostructure and Their Photoelectrochemical Application | |
孙留芳 | The Acceptance of Tanizaki Literature in Early Literature of Ikutoo | |
CN103762449A (zh) | 可转动插头 | |
YING | The Green Success of Xiangshui Eco-Chemical Industry Par |